Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNSR NASDAQ:LUCD NASDAQ:PSTV NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNSRLENSAR$12.35+2.4%$12.62$4.20▼$17.31$147.46M0.49120,889 shs36,740 shsLUCDLucid Diagnostics$1.03-1.0%$1.10$0.75▼$1.80$137.48M1.241.06 million shs579,335 shsPSTVPlus Therapeutics$0.62+9.6%$0.52$0.16▼$2.31$61.25M0.6619.96 million shs112.55 million shsRCELAvita Medical$5.20-2.5%$5.13$3.60▼$14.16$138.37M1.58394,387 shs106,121 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNSRLENSAR-0.66%-2.74%-4.21%-5.49%+172.23%LUCDLucid Diagnostics0.00%-2.80%-11.86%-11.11%+36.88%PSTVPlus Therapeutics+39.29%+30.60%+11.44%+78.67%-63.44%RCELAvita Medical+1.52%-3.79%+16.89%-2.20%-48.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNSRLENSAR$12.35+2.4%$12.62$4.20▼$17.31$147.46M0.49120,889 shs36,740 shsLUCDLucid Diagnostics$1.03-1.0%$1.10$0.75▼$1.80$137.48M1.241.06 million shs579,335 shsPSTVPlus Therapeutics$0.62+9.6%$0.52$0.16▼$2.31$61.25M0.6619.96 million shs112.55 million shsRCELAvita Medical$5.20-2.5%$5.13$3.60▼$14.16$138.37M1.58394,387 shs106,121 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNSRLENSAR-0.66%-2.74%-4.21%-5.49%+172.23%LUCDLucid Diagnostics0.00%-2.80%-11.86%-11.11%+36.88%PSTVPlus Therapeutics+39.29%+30.60%+11.44%+78.67%-63.44%RCELAvita Medical+1.52%-3.79%+16.89%-2.20%-48.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNSRLENSAR 2.00Hold$15.0021.56% UpsideLUCDLucid Diagnostics 3.00Buy$3.65252.66% UpsidePSTVPlus Therapeutics 3.20Buy$7.881,193.10% UpsideRCELAvita Medical 2.40Hold$11.60122.86% UpsideCurrent Analyst Ratings BreakdownLatest PSTV, LNSR, RCEL, and LUCD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/18/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/15/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.009/5/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $2.509/5/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $14.009/3/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/3/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.008/18/2025PSTVPlus TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/13/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/11/2025RCELAvita MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $8.008/8/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $18.00(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNSRLENSAR$53.49M2.75N/AN/A$0.42 per share29.38LUCDLucid Diagnostics$4.35M31.76N/AN/A($0.78) per share-1.33PSTVPlus Therapeutics$5.82M10.39N/AN/A($1.52) per share-0.40RCELAvita Medical$64.25M2.16N/AN/A$0.17 per share30.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNSRLENSAR-$31.40M-$4.21N/A∞N/A-84.49%-737.30%-72.60%11/6/2025 (Estimated)LUCDLucid Diagnostics-$45.53M-$1.19N/AN/AN/A-1,476.35%N/A-120.43%11/12/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)RCELAvita Medical-$61.85M-$1.97N/AN/AN/A-68.87%-632.62%-71.52%11/6/2025 (Estimated)Latest PSTV, LNSR, RCEL, and LUCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PSTVPlus Therapeutics-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 million8/7/2025Q2 2025LNSRLENSAR-$0.0750-$0.15-$0.0750-$0.15$16.55 million$11.36 million8/7/2025Q2 2025RCELAvita Medical-$0.26-$0.38-$0.12-$0.38$34.27 million$18.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNSRLENSARN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNSRLENSARN/A1.520.88LUCDLucid DiagnosticsN/A1.151.13PSTVPlus TherapeuticsN/A1.261.26RCELAvita Medical9.390.580.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNSRLENSAR40.15%LUCDLucid Diagnostics74.01%PSTVPlus Therapeutics3.28%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipLNSRLENSAR38.52%LUCDLucid Diagnostics6.80%PSTVPlus Therapeutics0.79%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNSRLENSAR11011.94 million7.34 millionOptionableLUCDLucid Diagnostics70133.48 million124.40 millionNo DataPSTVPlus Therapeutics2099.26 million98.48 millionNot OptionableRCELAvita Medical13026.62 million25.87 millionOptionablePSTV, LNSR, RCEL, and LUCD HeadlinesRecent News About These CompaniesAVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmSeptember 25 at 5:24 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical,September 24 at 9:39 PM | reflector.comRINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 24 at 4:12 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 23 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 18, 2025 | prnewswire.comAVITA Medical: Reimbursement Reset And Breakeven Path By 2026September 18, 2025 | seekingalpha.comAVITA Medical (RCEL): Valuation Insights Following RECELL GO’s CE Mark Approval and European Market ExpansionSeptember 17, 2025 | finance.yahoo.comAvita Medical (RCEL) Receives a Buy from TD CowenSeptember 17, 2025 | theglobeandmail.comD. Boral Capital Reiterates Buy Rating for Avita Medical (NASDAQ:RCEL)September 17, 2025 | americanbankingnews.comAvita Medical's (RCEL) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 16, 2025 | marketbeat.comAVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comD. Boral Capital Sticks to Their Buy Rating for Avita Medical (RCEL)September 14, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 13, 2025 | prnewswire.comRCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law FirmSeptember 11, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 10, 2025 | globenewswire.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comRCEL Alert: Kirby McInerney LLP Encourages AVITA Medical, Inc. Investors to Inquire about InvestigationSeptember 9, 2025 | businesswire.comAVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.com71,738 Shares in Avita Medical Inc. $RCEL Purchased by Nuveen LLCSeptember 6, 2025 | marketbeat.comAvita Medical says data shows hospital stay reduction with RCELL SystemSeptember 4, 2025 | msn.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmSeptember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025NVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 20253 Overlooked Value Stocks Set to Surge as Rates DropBy Gabriel Osorio-Mazilli | September 21, 2025PSTV, LNSR, RCEL, and LUCD Company DescriptionsLENSAR NASDAQ:LNSR$12.35 +0.29 (+2.40%) Closing price 04:00 PM EasternExtended Trading$12.35 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Lucid Diagnostics NASDAQ:LUCD$1.03 -0.01 (-0.96%) Closing price 04:00 PM EasternExtended Trading$1.04 +0.01 (+0.97%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Plus Therapeutics NASDAQ:PSTV$0.62 +0.05 (+9.61%) Closing price 04:00 PM EasternExtended Trading$0.60 -0.01 (-2.12%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Avita Medical NASDAQ:RCEL$5.20 -0.13 (-2.48%) Closing price 03:59 PM EasternExtended Trading$5.20 0.00 (-0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Why Wall Street Is Betting Billions on Oklo's Nuclear Vision CrowdStrike’s Investor Day Sparks Bullish Momentum Cintas Stock Sends a Clear Buy Signal as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
